Reacfin invites you to their event

Webinar #1 Scenario testing for ORSA: key take-away’s from COVID-19 crisis

About this event

Agenda:

  1. Purpose of the ORSA: test adequacy of own funds given insurer risk profile
  2. Reminder about the latest macro evolutions: understand what's going on
  3. How the latest developments might have impacted the insurer’s vulnerabilities
  4. Guidance on how to develop and calibrate scenarios for ORSA

Abstract:

Scenario testing is a key component of the ORSA process for insurance companies. Given the exceptional level of uncertainty ahead, considering a pertinent range of scenarios is a key step for insurers to prepare their management responses and make appropriate strategic decisions.

The main goal of the ORSA scenario testing is to assess the impact of plausible risk scenarios which are not captured by quantitative models. It helps insurance companies in preparing management actions and assess their plausibility given current/stress context.

This webinar deep dives into the latest macro evolutions to understand what’s going on and to show how the current developments might have impacted insurer’s vulnerabilities.

We will provide guidance on how to develop and calibrate scenarios to take these latest changes, as well as other rare events, into account in your ORSA.

Hosted by

  • Team member
    T
    Aurélie Miller Director @ Reacfin

  • Team member
    T
    Catherine Chatelain Manager @ Reacfin

  • Team member
    T
    Samuel Silber Senior Consultant @ Reacfin

  • Team member
    T
    Geoffrey Feraut Consultant @ Reacfin

  • Team member
    T
    Reacfin Academy

    Reacfin is a consulting firm focused on creating measurable value & results for its clients. Our mission is to develop innovative solutions to manage risks, products, capital & portfolios.

Reacfin

With Reacfin Academy, Unleash the power of Knowledge

Consulting, training & tools in Risk, Finance, Data Science and Actuarial Science. Bridging academic excellence with best market practices since 2004.